Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.

Clinical & experimental metastasis - 1 Jun 2020

Yang Haihong, He Dongyun, Wang Fengnan, Deng Qiuhua, Xie Zixian

Abstract excerpt

Brain metastases (BMs) are frequently occurred in lung adenocarcinoma with driver mutation. There is a need to explore multi-discipline treatments and prognostic factors in those patients with most frequent driver mutations: EGFR mutation and ALK fusion. In the retrospective study, different therapies and prognostic factors were compared between EGFR and ALK-driven lung adenocarcinoma with BMs. 516 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Kaplan-Meier Estimate

Share to Oncogene Proteins, Fusion

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 32356218
DOI: 10.1007/s10585-020-10026-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.PMID 32356218Read ↗

Title: Lung-molGPA in EGFR-mutated Adenocarcinoma: Prognostic Implications of Molecular Subtypes and Targeted TherapiesSemantic proximity Read ↗

Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.Semantic proximity Read ↗

A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?Semantic proximity Read ↗

[Targeted Therapies for Driver Gene Mutation-positive Lung Cancer Patients with Brain Metastasis].Semantic proximity Read ↗

The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study.Semantic proximity Read ↗

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesSemantic proximity Read ↗

Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations.Semantic proximity Read ↗

Advances in Lung Cancer Driver Genes Associated With Brain MetastasisSemantic proximity Read ↗

Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.Semantic proximity Read ↗

Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.Semantic proximity Read ↗

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.Semantic proximity Read ↗

Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.